Milla Maria Koistinaho
Fondateur chez Aranda Pharma Oy
Profil
Milla Maria Koistinaho is the founder of Aranda Pharma Oy, which was founded in 2015.
She is currently a Director at Valo Therapeutics Oy, a Director at Tribune Therapeutics AB, a Partner at Innovestor Oy, a Partner at Innovestor Ventures Oy, a Board Member at Teitur Trophics ApS, and a Board Member at Neumirna Therapeutics ApS.
Dr. Koistinaho's former positions include Chief Executive Officer at Charles River Discovery Research Services Finland Oy, Medeia Therapeutics Oy, and FIT Biotech Oy.
She was also a Board Member at Suomen Bioteollisuus ry from 2012 to 2022 and COO at Helsinki Innovation Services Ltd.
from 2017 to 2022.
Dr. Koistinaho holds a doctorate from the University of Kuopio and an undergraduate degree from the University of Eastern Finland.
Postes actifs de Milla Maria Koistinaho
| Sociétés | Poste | Début |
|---|---|---|
Aranda Pharma Oy
 Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | Fondateur | 01/09/2015 |
Valo Therapeutics Oy
 Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 01/01/2016 |
Innovestor Oy
 Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | Private Equity Investor | 01/04/2022 |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Directeur/Membre du Conseil | - |
Innovestor Ventures Oy
 Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | Private Equity Investor | 01/04/2022 |
| Neumirna Therapeutics ApS | Directeur/Membre du Conseil | 01/12/2022 |
Teitur Trophics ApS
 Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | Directeur/Membre du Conseil | 02/03/2023 |
Anciens postes connus de Milla Maria Koistinaho
| Sociétés | Poste | Fin |
|---|---|---|
Helsinki Innovation Services Ltd.
 Helsinki Innovation Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of University of Helsinki, Helsinki Innovation Services Ltd. is a company that provides business and innovation-related consulting services. The company is based in Helsinki, Finland. | Directeur des opérations | 30/04/2022 |
| Suomen Bioteollisuus ry | Directeur/Membre du Conseil | 30/04/2022 |
| ░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Milla Maria Koistinaho
| University of Kuopio | Doctorate Degree |
| University of Eastern Finland | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
FIT Biotech Oy
 FIT Biotech Oy BiotechnologyHealth Technology FIT Biotech Oy engages in the business of researching, developing, and manufacturing diagnostic laboratory tests and pharmaceutical products. The firm is also involved in marketing gene transport unit vector technology to be used as a gene transport mechanism in gene therapeutic applications. The company was founded on May 17, 1995 and is headquartered in Tampere, Finland. | Health Technology |
Charles River Discovery Research Services Finland Oy
 Charles River Discovery Research Services Finland Oy Miscellaneous Commercial ServicesCommercial Services Charles River Discovery Research Services Finland Oy provides non-clinical central nervous system services to the pharmaceutical and biotechnology industries. The company was founded in 1998 and is located in Kuopio, Finland. | Commercial Services |
Medeia Therapeutics Oy
 Medeia Therapeutics Oy Miscellaneous Commercial ServicesCommercial Services Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^ | Commercial Services |
| Suomen Bioteollisuus ry | |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | Health Technology |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | Finance |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | Finance |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Health Technology |
Helsinki Innovation Services Ltd.
Helsinki Innovation Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of University of Helsinki, Helsinki Innovation Services Ltd. is a company that provides business and innovation-related consulting services. The company is based in Helsinki, Finland. | Commercial Services |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Commercial Services |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | Health Technology |
| Neumirna Therapeutics ApS | Health Technology |
